{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:20:53Z","timestamp":1778613653559,"version":"3.51.4"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.2169\/internalmedicine.4427-24","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T22:13:56Z","timestamp":1735164836000},"page":"2046-2050","source":"Crossref","is-referenced-by-count":3,"title":["Alternating Administration of Osimertinib for Leptomeningitis and Docetaxel Plus Ramucirumab for Lung Adenocarcinoma Resistant to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors"],"prefix":"10.2169","volume":"64","author":[{"given":"Haruka","family":"Tomizawa","sequence":"first","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuto","family":"Mouri","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Mikoshiba","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasumi","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miku","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamana","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozo","family":"Suhara","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Kamimura","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, National Hospital Organization Disaster Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yang JC, Kim SW, Kim DW, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol 38: 538-547, 2020.","DOI":"10.1200\/JCO.19.00457"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ahn MJ, Chiu CH, Cheng Y, et al. Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis. J Thorac Oncol 15: 637-648, 2020.","DOI":"10.1016\/j.jtho.2019.12.113"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. McLean LS, Faisal W, Parakh S, et al. Standard-dose osimertinib in EGFR-mutated non-small-cell lung adenocarcinoma with leptomeningeal disease. JCO Precis Oncol 5: 561-568, 2021.","DOI":"10.1200\/PO.20.00464"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Li YS, Jiang BY, Yang JJ, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 11: 1962-1969, 2016.","DOI":"10.1016\/j.jtho.2016.06.029"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Umemura S, Tsubouchi K, Yoshioka H, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 77: 134-139, 2012.","DOI":"10.1016\/j.lungcan.2012.03.002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Goss G, Tsai CM, Shepherd FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol 29: 687-693, 2018.","DOI":"10.1093\/annonc\/mdx820"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Du C, Hong R, Shi Y, Yu X, Wang J. Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients. J Neurooncol 115: 285-291, 2013.","DOI":"10.1007\/s11060-013-1228-x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Liao BC, Lee JH, Lin CC, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol 10: 1754-1761, 2015.","DOI":"10.1097\/JTO.0000000000000669"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yufen X, Binbin S, Wenyu C, Jialiang L, Xinmei Y. The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus 5: 1244, 2016.","DOI":"10.1186\/s40064-016-2873-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol 36: 2702-2709, 2018.","DOI":"10.1200\/JCO.2018.77.9363"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nanjo S, Hata A, Okuda C, et al. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer 118: 32-37, 2018.","DOI":"10.1038\/bjc.2017.394"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lee J, La Choi Y, Han J, et al. Osimertinib improves overall survival in patients with EGFR-mutated NSCLC with leptomeningeal metastases regardless of T790M mutational status. J Thorac Oncol 15: 1758-1766, 2020.","DOI":"10.1016\/j.jtho.2020.06.018"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Saboundji K, Auliac JB, P\u00e9rol M, et al. Efficacy of osimertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastases pretreated with EGFR-tyrosine kinase inhibitors. Target Oncol 13: 501-507, 2018.","DOI":"10.1007\/s11523-018-0581-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chen J, Soudy H. Osimertinib in the treatment of leptomeningeal disease in T790M-negative, epidermal growth factor receptor-mutated non-small cell lung cancer: a case report. Chin Clin Oncol 8: 29, 2019.","DOI":"10.21037\/cco.2019.02.02"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 36: 3290-3297, 2018.","DOI":"10.1200\/JCO.2018.78.3118"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Planchard D, J\u00e4nne PA, Cheng Y, et al; the FLAURA2 Investigators. Osimertinib with or without chemotherapy in <i>EGFR<\/i>-mutated advanced NSCLC. N Engl J Med 389: 1935-1948, 2023.","DOI":"10.1056\/NEJMoa2306434"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Planchard D, Feng PH, Karaseva N, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced\/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open 6: 100271, 2021.","DOI":"10.1016\/j.esmoop.2021.100271"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. J\u00e4nne PA, Planchard D, Kobayashi K, et al. CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer. J Clin Oncol 42: 808-820, 2024.","DOI":"10.1200\/JCO.23.02219"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lim SM, Fujino T, Kim C, et al. BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant EGFR mutations in non-small cell lung cancer. Clin Cancer Res 29: 3004-3016, 2023.","DOI":"10.1158\/1078-0432.CCR-22-3901"},{"key":"20","unstructured":"20. Nakagawa K, Garon EB, Seto T, et al; the RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, <i>EGFR<\/i>-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20: 1655-1669, 2019."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 38: 115-123, 2020.","DOI":"10.1200\/JCO.19.01488"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20: 625-635, 2019.","DOI":"10.1016\/S1470-2045(19)30035-X"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Zhou K, Zhao S, Guo W, Ding L. Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Medicine (Baltimore) 99: e18771, 2020.","DOI":"10.1097\/MD.0000000000018771"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tsuchiya K, Karayama M, Yasui H, et al. An acquired epidermal growth factor receptor T790M mutation after the addition of bevacizumab to preceding erlotinib monotherapy in a lung cancer patient with leptomeningeal metastases. Intern Med 57: 3423-3427, 2018.","DOI":"10.2169\/internalmedicine.1062-18"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chiba S, Akiyama M, Yakuwa K, et al. Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report. Ann Palliat Med 11: 2745-2750, 2022.","DOI":"10.21037\/apm-21-1885"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ariyasu R, Horiike A, Koyama J, et al. Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib. Anti-Cancer Drugs 28: 565-567, 2017.","DOI":"10.1097\/CAD.0000000000000489"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/13\/64_4427-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:46:09Z","timestamp":1751687169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/13\/64_4427-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":26,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4427-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"4427-24"}}